高级搜索
王芳, 周开甲, 赵征, 梁晖, 刘彦伟. 内向整流型钾离子通道亚家族J成员11 mRNA在脑胶质瘤中的表达及预测预后价值[J]. 肿瘤防治研究, 2022, 49(1): 18-23. DOI: 10.3971/j.issn.1000-8578.2022.21.0574
引用本文: 王芳, 周开甲, 赵征, 梁晖, 刘彦伟. 内向整流型钾离子通道亚家族J成员11 mRNA在脑胶质瘤中的表达及预测预后价值[J]. 肿瘤防治研究, 2022, 49(1): 18-23. DOI: 10.3971/j.issn.1000-8578.2022.21.0574
WANG Fang, ZHOU Kaijia, ZHAO Zheng, LIANG Hui, LIU Yanwei. Expression and Prognostic Value of Inward Rectifier Potassium Channel Subfamily J Member 11 mRNA in Gliomas[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 18-23. DOI: 10.3971/j.issn.1000-8578.2022.21.0574
Citation: WANG Fang, ZHOU Kaijia, ZHAO Zheng, LIANG Hui, LIU Yanwei. Expression and Prognostic Value of Inward Rectifier Potassium Channel Subfamily J Member 11 mRNA in Gliomas[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 18-23. DOI: 10.3971/j.issn.1000-8578.2022.21.0574

内向整流型钾离子通道亚家族J成员11 mRNA在脑胶质瘤中的表达及预测预后价值

Expression and Prognostic Value of Inward Rectifier Potassium Channel Subfamily J Member 11 mRNA in Gliomas

  • 摘要:
    目的 分析KCNJ11 mRNA在脑胶质瘤中的表达及其预测预后价值。
    方法 收集CGGA数据库中273例脑胶质瘤患者临床、组织病理及分子病理特征,分析不同类型患者KCNJ11 mRNA表达差异,以及不同亚型患者中KCNJ11 mRNA高表达与低表达患者生存时间差异。
    结果 脑胶质瘤患者年龄越大KCNJ11 mRNA表达越低(P=0.008),原发胶质瘤KCNJ11 mRNA表达高于复发胶质瘤(P=0.001)。少枝胶质细胞瘤KCNJ11 mRNA表达 > 星形细胞瘤 > 胶质母细胞瘤(P=0.000)。WHOⅡ级KCNJ11 mRNA表达 > WHOⅢ级 > WHOⅣ级(P=0.000)。IDH突变型KCNJ11 mRNA表达高于IDH野生型(P=0.000)。1p/19q缺失型KCNJ11 mRNA表达高于1p/19q不缺失型(P=0.000)。MGMT甲基化KCNJ11 mRNA高于无甲基化(P=0.036)。KCNJ11 mRNA高表达患者(≥2.77)生存期长于低表达患者(< 2.77)(P=0.000)。多因素Cox分析提示KCNJ11 mRNA高表达是脑胶质瘤患者良好预后的独立影响因素。
    结论 脑胶质瘤恶性程度越高,KCNJ11 mRNA表达越低。KCNJ11 mRNA高表达是影响脑胶质瘤患者良好预后的独立影响因素。

     

    Abstract:
    Objective To analyze the expression of KCNJ11 mRNA in gliomas and its prognostic value.
    Methods The clinical, histopathological and molecular pathological features of 273 patients with gliomas were collected from CGGA. We analyzed the differences of KCNJ11 mRNA expression in different types of gliomas and the survival time of patients with high and low expression of KCNJ11 mRNA in different subtypes of gliomas.
    Results The expression levels of KCNJ11 mRNA in young glioma and primary glioma patients were higher than those in old glioma and recurrent glioma patients, respectively (P=0.008, 0.001). The expression of KCNJ11 mRNA in oligodendroglioma was the highest, astrocytoma was the second, and glioblastoma was the lowest (P=0.000). The expression of KCNJ11 mRNA in WHOⅡ grade glioma was the highest, WHOⅢ was the second, and WHOⅣ was the lowest (P=0.000). The expression levels of KCNJ11 mRNA in IDH-mutant type glioma patients were higher than those in IDH-wild type glioma patients (P=0.000). The expression of KCNJ11 mRNA in deletion of 1p/19q glioma patients was higher than that in non-deletion of 1p/19q ones (P=0.000). The expression of KCNJ11 mRNA in MGMT methylated glioma patients was higher than that in non-methylated ones (P=0.036). The survival time of patients with high expression of KCNJ11 mRNA (≥2.77) was longer than that with low expression (P=0.000). Multivariate Cox analysis showed that the high expression of KCNJ11 mRNA was an independent factor affecting the good prognosis of patients with glioma.
    Conclusion The expression of KCNJ11 mRNA is negatively related to the malignant degree of the tumor. The high expression of KCNJ11 mRNA is an independent factor affecting the good prognosis of patients with glioma.

     

/

返回文章
返回